How to Control Impurities during API drug manufacturing
Posted: February 19, 2018
Dr. Rajesh Shukla, Vice President Research and Development at PCI Synthesis Talks about Controlling Impurities during API drug manufacturing.
Related posts:
PCI Synthesis at DCAT Week 2017
How to Know when to Toss your Prescription Drug or Refrigerate it
Making the Right Connections inside Massachusetts for Business Development
What’s Behind Rising Drug Prices and What Can Be Done To Control Them?
Seqens CDMO North America Honored for Service Excellence for 6th Straight Year
About the Author
Ed is President & CEO of SEQENS North America (formerly PCI Synthesis). He serves as a co-chair of the New England CRO/CMO Council and sits on the Industrial Advisory Board for the Department of Chemical Engineering at UMass, Amherst. Ed is also a long standing member of the American Chemical Society and advises the Bulk Pharmaceutical Task Force of the Society of Chemical Manufacturer’s and Affiliates (SOCMA)...